Orchard Therapeutics gene therapy Lenmeldy won FDA approval for treating the rare enzyme deficiency metachromatic leukodystrophy. In January, Kyowa Kirin completed its acquisition of Orchard, which now operates as a subsidiary of the Japanese drugmaker.
The Orchard Therapeutics acquisition comes as the biotech’s gene therapy for metachromatic leukodystrophy approaches a March 2024 FDA decision. The ex vivo gene therapy is already commercialized in Europe, marketed as Libmeldy.
This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.
The London-based biotech would trade on the Nasdaq under the ticker symbol ORTX. The move comes two months after it closed a $150 million Series C and five months after it acquired a gene therapy portfolio from GSK.
The oversubscribed round comes just four months after acquisition of GSK's gene therapy portfolio.